The Future
of Clinical Trial Imaging Has Arrived

The team’s experience working at clinical research sites comes through in the responsiveness to any and all inquiries from us as the sponsor and the clinical sites directly, and aligning under Voiant has expanded their global footprint and ability to augment global trial needs.”

Dr. Jason Slakter and the Voiant team have become truly collaborative and essential partners, providing expert services and advice during every stage of our clinical development journey from Phase 1 and 2 and currently through execution of large global Phase 3 clinical trials. We look forward to our continued collaboration with Voiant.”

I am grateful for the outstanding services provided by Voiant. The Voiant team provided invaluable expertise in guiding the design and operational considerations of a blinded independent central review of imaging for our unique pediatric oncology registration program. Their proficiency in this specialized area significantly enhanced the reliability and accuracy of our research data. As a result of the high standards of their process and strong execution, the outcomes of the BICR were unequivocally successful and provided vital support for FDA agreement with the contents of our planned efficacy package for review. Voiant’s contributions certainly elevated the quality of our research to bring us a step closer to our product registration goal, and we highly recommend their services to anyone seeking a qualified and reliable and imaging services vendor. We look forward to a future opportunity to collaborate with Voiant.